Nuvalent - Public Comps and Valuation Multiples

Nuvalent Overview

About Nuvalent

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Founded

2017

HQ

Employees

142

Website

nuvalent.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue n/a

LTM EBITDA -$373M

EV

$5.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Nuvalent Financials

As of September 2025, Nuvalent reported last 12-month EBITDA of -$373M.

In the same period, Nuvalent achieved -$359M in LTM net income.

See Nuvalent valuation multiples based on analyst estimates

Nuvalent P&L

In the most recent fiscal year, Nuvalent reported EBITDA of -$280M.

Nuvalent expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Nuvalent valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	n/a	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$373M	XXX	-$280M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$390M	XXX	-$280M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Profit	-$359M	XXX	-$261M	XXX	XXX	XXX
Net Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Nuvalent including revenue, profitability, and margin analysis across different time periods. EBITDA for the last twelve months was -$373M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$373M	Analyst estimates available to subscribers	-$280M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$390M	Analyst estimates available to subscribers	-$280M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$359M	Analyst estimates available to subscribers	-$261M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Nuvalent

This financial data table provides comprehensive performance metrics for Nuvalent, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

The company achieved -$373M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$359M.

Fiscal Year Performance

Fiscal year EBITDA was -$280M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Nuvalent. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Nuvalent Stock Performance

Nuvalent has current market cap of $6.7B, and EV of $5.7B.

Market Cap Evolution

Nuvalent Stock Data

As of October 17, 2025, Nuvalent's stock price is $93.

See Nuvalent trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$5.7B	$6.7B	XXX	XXX	XXX	XXX	$-5.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Nuvalent Valuation Multiples

Nuvalent's trades at n/a EV/Revenue multiple, and -20.2x EV/EBITDA.

See valuation multiples for Nuvalent and 15K+ public comps

Nuvalent Financial Valuation Multiples

As of October 17, 2025, Nuvalent has market cap of $6.7B and EV of $5.7B.

Equity research analysts estimate Nuvalent's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Nuvalent has a P/E ratio of -18.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$6.7B	XXX	$6.7B	XXX	XXX	XXX
EV (current)	$5.7B	XXX	$5.7B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	-15.2x	XXX	-20.2x	XXX	XXX	XXX
EV/EBIT	-14.5x	XXX	-20.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-18.6x	XXX	-25.6x	XXX	XXX	XXX
EV/FCF	-48.8x	XXX	-30.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Nuvalent Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Nuvalent Margins & Growth Rates

Nuvalent's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.

Nuvalent's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Nuvalent's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Nuvalent and other 15K+ public comps

Nuvalent Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	10%	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$2.0M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial